Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EPS (Basic): 2012-2024

Historic EPS (Basic) for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $3.29.

  • Amphastar Pharmaceuticals' EPS (Basic) fell 54.22% to $0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.36, marking a year-over-year decrease of 27.38%. This contributed to the annual value of $3.29 for FY2024, which is 15.44% up from last year.
  • Amphastar Pharmaceuticals' EPS (Basic) amounted to $3.29 in FY2024, which was up 15.44% from $2.85 recorded in FY2023.
  • Amphastar Pharmaceuticals' 5-year EPS (Basic) high stood at $3.29 for FY2024, and its period low was $0.03 during FY2020.
  • For the 3-year period, Amphastar Pharmaceuticals' EPS (Basic) averaged around $2.67, with its median value being $2.85 (2023).
  • Per our database at Business Quant, Amphastar Pharmaceuticals' EPS (Basic) tumbled by 97.12% in 2020 and then soared by 4,233.33% in 2021.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' EPS (Basic) stood at $0.03 in 2020, then spiked by 4,233.33% to $1.30 in 2021, then soared by 44.62% to $1.88 in 2022, then skyrocketed by 51.60% to $2.85 in 2023, then grew by 15.44% to $3.29 in 2024.